Clinico-histopathologic and single nuclei RNA sequencing insights into cardiac injury and microthrombi in critical COVID-19

Michael I. Brener†, Michelle L. Hulke†, Nobuaki Fukuma†, Stephanie Golob, Robert Zilinyi, Zhipeng Zhou, Christos Tzimas, Ilaria Russo, Claire McGroder, Ryan Pfeiffer, Alexander Chong, Geping Zhang, Daniel Burkhoff, Martin B. Leon, Mathew Maurer, Jeffrey W. Moses, Anne-Catrin Uhlemann, Hanina Hibshoosh, Nir Uriel, Matthias J. Szabolcs, Björn Redfors, Charles C. Marboe, Matthew R. Baldwin, Nathan R. Tucker, Emily J. Tsai

1Division of Cardiology, Columbia University Irving Medical Center, New York, NY; 2Masonic Medical Research Institute, Utica, NY; 3Department of Medicine, Columbia University College of Physicians & Surgeons, New York, NY; 4Cardiovascular Research Foundation, New York, NY; 5Division of Pulmonary, Allergy & Critical Care Medicine, Columbia University Irving Medical Center, New York, NY; 6Division of Infectious Diseases and 7Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY; 8St. Francis Hospital Heart Center, Roslyn, NY; 9Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA.

†Drs. Brener, Hulke, and Fukuma all contributed equally as co-first authors.
‡Drs. Tsai and Tucker contributed equally as co-senior authors.

*Addresses for correspondence:
Emily J. Tsai, Division of Cardiology, Columbia University Vagelos College of Physicians & Surgeons, VP&S 8-510, 630 West 168th St, New York, NY 10032, Phone +01-212-305-3409; et2509@cumc.columbia.edu.
Nathan R. Tucker, Masonic Medical Research Institute, 2150 Bleecker St, Utica, NY 13501, Phone +01-315-624-7476, ntucker@mmri.edu
| Items                                      | Pages |
|--------------------------------------------|-------|
| Supplemental Methods                       | 3     |
| Supplemental Tables                        |       |
| Table 1: Cardiac histopathology and ventricular viral load of COVID-19 decedents | 9     |
| Table 2: Association between microthrombi and other acute histopathologic features at the ventricular level | 10    |
| Table 3: Association between detectable SARS-CoV-2 and acute histopathologic features at the ventricular level | 11    |
| Table 4: Association between cardiac microthrombi and ESR as a categorical variable | 12    |
| Table 5: Clinical characteristics of COVID-19 (+) snRNAseq subsets | 13    |
| Table 6: Sample level quality control metrics for snRNAseq | 14    |
| Table 7: Marker genes by cell type for snRNAseq | 15    |
| Table 8: Compositional analysis from snRNAseq using scCODA comparing COVID-19(+) vs. COVID-19(-) reference samples | 16    |
| Table 9: Compositional analysis from snRNAseq using scCODA comparing COVID-19(+) samples with vs. without microthrombi | 17    |
| Table 10: Differentially expressed genes identified by snRNAseq | 18    |
| Table 11: Gene set enrichment analysis by cell type and condition using ReactomeDB | 18    |
| Table 12: Cell-cell communication as assessed through CellphoneDB | 18    |
| Table 13: Regulator genes identified by Genewalk for COVID-19 (+) vs. (-) and microthrombi (+) vs. microthrombi (-) COVID-19 subsets | 18    |
| Supplemental Figures                       |       |
| Figure 1: Forest plot of the association between outpatient and in-hospital treatments and cardiac microthrombi | 19    |
| Figure 2: Principal components analysis of sample level transcript abundance | 20    |
| Figure 3: Identification and removal of low-quality nuclei in snRNAseq data | 21    |
| Figure 4: Volcano plots displaying differential expression results for presence of COVID-19 and for presence of microthrombi | 22    |
| Figure 5: Genewalk regulators for COVID-19(+) vs. COVID-19(-) reference samples | 23    |
| Figure 6: Ontology analysis for select regulator genes identified by Genewalk | 24    |
| Figure 7: Ventricular expression of FAP and POSTN in COVID-19(+) samples with vs. without microthrombi (PMI<24 hrs) | 25    |
| Supplemental References                   | 26    |
Supplemental Methods

Low Post-Mortem Interval (PMI) Initiative

During the initial COVID-19 surge in New York City, the Columbia University Irving Medical Center (CUIMC) Departments of Pathology and Medicine implemented a multi-disciplinary initiative to lower post-mortem interval (PMI). Clinicians directly involved in the care of decedents obtained autopsy consent from next-of-kin at the time of death notification or shortly thereafter. Witnessed verbal consent was approved and accepted by New York Presbyterian-CUIMC since all hospital visitations were prohibited during this period. Documentation of informed autopsy consent was protocolized for the electronic medical record; a copy of the document was sent to the decedents’ next-of-kin by electronic or postal mail. Timely transfer to the autopsy suite was coordinated immediately upon attainment of autopsy consent. Infographics, cloud-based resources, and multiple daily HIPAA-compliant text communications to frontline clinicians were created and used to support the low PMI initiative.

Measurement of ventricular SARS-CoV-2 viral load

Total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue samples of left (LV) and right ventricles (RV) of all 69 hearts, using the Quick-RNA FFPE Miniprep Kit (Zymo Research, Irvine, CA) according to the manufacturer’s instructions. RNA elution was performed with nuclease free double-distilled H₂O at a final volume of 75 μl. We performed quantitative reverse transcription-polymerase chain reaction (RT-qPCR), using primer/probe sets for the N1 and N2 regions of the SARS-CoV-2 nucleocapsid gene and for the human RNase P gene (RP) (Integrated DNA Technologies), as described previously (1). All samples were run in triplicate. A standard curve of N2 ranging from 10¹-10⁵ viral copies was generated from the 2019-nCoV_N_Positive Control (Integrated DNA Technologies, Coralville, IA). Samples
were considered positive for SARS-CoV-2 only if all three transcripts---\( N1, N2, \) and \( RP \)---were detected.

For each RT-qPCR reaction, we used 5 μL of the total 75 μL of extracted RNA per ventricular tissue sample. Hence, the calculated viral load of each \( N2 \) RT-qPCR reaction was multiplied by 15 to yield the ventricular viral load of the sample. To account for potential differences in ventricular tissue sample sizes, ventricular viral loads were normalized to \( RP \) expression using the \( \Delta \) cycle threshold (Ct) method. Specifically, a normalization ratio for \( RP \) expression was calculated as \( 2^{-\Delta Ct} \), whereby \( \Delta Ct \) was the difference between each sample’s \( RP \) Ct and the mean \( RP \) Ct of all samples. Thus, the normalized viral load for each ventricular tissue sample was calculated by dividing the raw ventricular viral load by the normalization ratio.

**RT-qPCR of canonical genes of fibroblast activation**

Total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue samples of the RV of all COVID-19 hearts for which PMI was less than 24 hours. Total RNA was extracted using the Quick-RNA FFPE Miniprep Kit (Zymo Research, Irvine, CA) according to the manufacturer’s instructions. Only those samples with detectable housekeeping genes GAPDH and RPS13 were included in summary analysis.

**Data Processing of single nuclei RNA sequences**

Raw base call sequencing files were de-multiplexed; FASTQ files were generated using the 10x Genomics CellRanger 4.0.0 in the Cumulus workflow (2). To remove homopolymers (A30, T30, G30, and C30) and the template switch oligo sequence (CCCATGTACTCTGCGTTGATACCACTGCTT and its complement AAGCAGTGGTATCAACGCAGA GTACATGGG), reads were trimmed using Cutadapt v2.8 (3) with default parameters. Trimmed reads were aligned to the GRCh38 pre-mRNA human reference with SARS-CoV2 annotations (NC_045512). Count matrices were generated using CellRanger Count v12.
We inspected each sample for mapping quality based on the number of mapped reads per nucleus, percentage of mapped mitochondrial reads (% mitochondrial reads), and the shape of the unique molecular identifier (UMI) decay curve. One sample (SID 69-RV) demonstrated high levels of mitochondrial reads and was removed from further analyses. The remaining samples were filtered using CellBender v2.0 (4) with default settings to remove the ambient RNA byproducts of nuclear isolation. From this, 108,016 nuclei remained.

Quality control was performed on the individual sample level. For each droplet, we calculated the ratio of reads mapping to exonic regions to total mapped reads using Scrinvex v13 (https://github.com/getzlab/scrinvex). Droplets with an exon ratio greater than the 75th percentile + IQR range were removed from downstream analyses due to increased cytoplasmic transcripts (3,182 nuclei). We also excluded droplets which contained more than one nucleus as identified by Scrublet (5) (10,866 nuclei). Samples were also filtered to remove nuclei with reads mapped to less than 200 genes (11,280 nuclei) and nuclei with greater than 5% mitochondrial reads (9,825 nuclei).

The gene list was filtered for highly variable genes (minimum mean 0.0125, maximum mean 3, minimum dispersion 0.5), using a subset of 6,255 genes for graph-based clustering. To account for variable complexity per nucleus, counts were normalized to 10,000 unique molecules per nucleus and logarithmized. Total read count and % mitochondrial reads were regressed out (Scanpy preprocessing `regress_out`); data was scaled to a maximum value of 10.

Ischemic time for non-COVID-19 reference controls (6) was unavailable. Hence, we could not account for effects of ischemic time; results relating to hypoxic signaling should be interpreted with caution.

We calculated principal components from the highly variable gene subset (scanpy.tl.pca(adata, svd_solver='arpack')) and then corrected the normalized data for batch
effects using Harmonypy version 0.0.5 (7) with each sample considered as a unique batch. We used the batch-corrected PCs to calculate neighbors (scanpy.pp.neighbors(adata, n_neighbors=10, n_pcs=40)) and generate a UMAP (scanpy.tl.umap(adata)). Nuclei were then clustered using leiden clustering (scanpy.tl.leiden(adata)) at a resolution of 0.225.

**Marker gene and cell type identification**

Genes were ranked using a Wilcoxon rank sum test (scanpy rank_genes_groups) for each cell-type cluster versus all others; and log₂-fold change (FC) and percentage of nuclei expressing each gene were calculated. Area under the receiver operator curve (AUC) scores were calculated for all genes within each cluster using SciKit Learn roc_auc_score. Genes were considered markers of a given cluster with an AUC score >0.7 or a log₂-FC >0.6.

**Compositional analyses**

The proportion of each cell type was compared across samples using scCODA version 0.1.1 (8). Briefly, we constructed a Markov-Chain Monte Carlo model with Hamiltonian Monte Carlo sampling using cell type proportions between conditions (non-COVID-19 reference control versus COVID-19, or COVID-19 microthrombi-positive versus COVID-19 microthrombi-negative). Credible interval differences in cell type proportions were determined using spike-and-slab inclusion probabilities. Importantly, the proportion of a given cell type in a sample is governed by our ability to liberate the nuclei equivalently from the tissue and our ability to successfully identify cells compared to empty droplets. The former may be affected by cell death or increased fibrosis which our sectioning protocol is designed to mitigate. The latter is a more challenging problem for single nucleus RNA sequencing, which is influenced by the relative transcriptional complexity of various cell types, making transcript rich cell types such as cardiomyocytes and fibroblasts easy to identify with transcript poor cells such as immune cells more apt to be assigned as an empty droplet. Use of a probabilistic cell calling mechanism in CellBender(4) is used to overcome this challenge.
**Differential expression testing**

Differentially expressed genes (DEGs) were calculated for each major cell cluster separately using the MAST(9) pipeline. We constructed a Hurdle model (zlm(~condition +ngen + (1 | sample_ID), sca, method='glmer', ebayes = FALSE, strictConvergence = FALSE)) with the normalized reads based on the cellular detection rate, the set condition (either donor control versus COVID-19, or COVID-19 microthrombi-positive versus COVID-19 microthrombi-negative), and biological individual. Only genes with non-zero expression in at least 15% of all nuclei were included. DEGs were identified based on a Benjamini-Hochberg false discovery rate (FDR) adjusted P-value <0.05. Importantly, each droplet is contaminated by ambient RNA, which is imperfectly removed informatically by design. Therefore, DE results should be interpreted with caution, particularly when examining non-major cell types (e.g., intracardiac neurons, lymphatic endothelial, mast cells) and genes highly expressed in those as numerous as cardiomyocytes. Genes which serve as markers of another cluster (AUC ≥ 0.7) were blacklisted to exclude potential differential contamination by ambient RNA as a driver of such effect. Gene lists were also compared to the secreted protein list obtained from the Human Protein Atlas (proteinatlas.org). Full lists of DE genes, including those which were blacklisted, are contained in Supplemental Table ST3.

**Reactome pathway enrichment**

For each major cell type, we performed gene pathway enrichment using Reactome(10) (Pathway browser version 3.7, database release 75) on DEGs with log2-FC >0.25, separated into up or downregulated genes. We also calculated pathway enrichment using the Reactome pathway from GSEA Msigdb(11) (MSigDB database v7.2). Pathways were considered enriched within a cell type if identified as such by both Reactome and GSEA Msigdb (BH FDR adjusted
P-value of $\leq 0.05$). Reactome terms for all comparisons are available in Supplemental Table ST11.

**Cell-Cell Communication**

Cell-cell communication was tested with CellphoneDB version 2.1.7 (12) on each sample separately using normalized count data for the 9 largest cell types. Afterward, significant interactions were aggregated between microthrombi-positive and microthrombi-negative samples. Briefly, CellphoneDB identifies and compares ligand-receptor interaction pairs between cell types and compares the observed interactions to the expected interactions of a null distribution generated from randomly permuted cell labels. Default parameters were used for the analysis (10% threshold for cells expressing ligands and receptors, p-value = 0.05, 1000 iterations for generation of null distribution, curated interactions list compiled by CellphoneDB from UniProt, Ensembl, PDB, IMEx consortium, and IUPHAR).

**Regulator Genes**

To identify regulator genes that function within and likely drive gene networks within a biological context, we analyzed DEGs with a $\log_2$-FC $\geq 0.5$ for each cell type using GeneWalk(13) (direction of differential expression was not incorporated). GeneWalk builds biologically relevant networks from provided gene lists, connecting genes and GO terms, and compares the network to random networks. GeneWalk was used with default parameters and an FDR-corrected P-value of 0.1. The identified regulator genes were compared to a list of druggable genes.(14) The full list of regulator genes identified is available in Supplemental Table 13.
Supplemental Table 1. Cardiac histopathology and ventricular viral load of COVID-19 decedents

| COVID-19 | Overall (n=69) | Microthrombi-Positive* (n=48) | Microthrombi-Negative (n=21) |
|----------|----------------|-------------------------------|-----------------------------|
| **Ventricular Viral load** | | | |
| Detectable viral load | 43 (62.3) | 31 (64.5) | 12 (57.1) |
| SARS-CoV-2 viral load* (copies) | 1055 [307, 13285] | 1594 [562,13285] | 387 [196, 21811] |
| **Cardiac Autopsy Findings, n(%)** | | | |
| Left ventricular hypertrophy | 45 (65.2) | 34 (70.8) | 11 (52.4) |
| Left ventricular dilation | 18 (26.1) | 16 (33.3)§ | 2 (9.5) |
| Right ventricular hypertrophy | 21 (30.4) | 16 (33.3) | 5 (23.8) |
| Right ventricular dilation | 37 (53.6) | 27 (56.3) | 10 (47.6) |
| Coronary atherosclerosis | 39 (56.5) | 26 (54.2) | 13 (61.9) |
| Myocardial infarction | 14 (20.3) | 10 (20.8) | 4 (19.0) |
| Thrombus† | 2 (2.9) | 2 (4.2) | 0 (0.0) |
| Interstitial edema | 5 (7.2) | 3 (6.3) | 2 (9.5) |
| Perivascular fibrosis | 23 (33.3) | 16 (33.3) | 7 (33.3) |
| Interstitial fibrosis | 27 (39.1) | 21 (43.8) | 6 (28.6) |
| Wavy myocytes | 7 (10.1) | 3 (6.3) | 4 (19.0) |
| Contraction bands | 5 (7.2) | 3 (6.3) | 2 (9.5) |
| Pericardial findings | 12 (17.4) | 8 (16.7) | 4 (19.0) |
| **Cardiac Histopathologic Findings†, n(%)** | | | |
| Microvascular endothelial cell damage | 25 (36.2) | 19 (39.6)§ | 6 (28.6) |
| Scattered individual cardiomyocyte necrosis | 25 (36.2) | 16 (33.3) | 9 (42.8) |
| Focal cardiac necrosis | 14 (20.3) | 11 (22.9) | 3 (14.3) |
| Focal inflammatory infiltrate | 12 (17.4) | 6 (12.5) | 6 (28.6) |
| Focal myocarditis | 4 (5.8) | 2 (4.2) | 2 (9.5) |
| **Pulmonary Autopsy Findings, n(%)** | | | |
| Diffuse alveolar damage | 38 (55.1) | 27 (56.3) | 11 (52.4) |
| Pulmonary artery thrombosis | 10 (14.5) | 7 (14.6) | 3 (14.3) |
| Pulmonary microvascular thrombi | 42 (60.9) | 31 (64.6) | 11 (52.4) |

Data are presented as counts with percentages in parenthesis and median with interquartile range in brackets.

* Based upon the higher value detected in either the left or right ventricle of decedent
† Intraventricular, intra-atrial, or epicardial coronary arterial thrombus
‡ Based upon detection in either left or right ventricle of decedent
§ P<0.05
**Supplemental Table 2. Association between microthrombi and other acute histopathologic features at the ventricular level.**

| Dependent Variable                  | Independent Variable                      | Univariate Model | Multivariate Model |
|-------------------------------------|-------------------------------------------|------------------|--------------------|
|                                     |                                            | OR (95% CI)      | p                  | OR (95% CI)      | p        |
| Microthrombi                        | Microvascular endothelial cell damage     | 3.44 (1.42, 8.32) | 0.006              | 3.58 (1.46, 8.80) | 0.005    |
| Scattered individual necrotic cardiomyocytes | Microthrombi                          | 1.00 (0.46, 2.20) | 1.00               | 1.05 (0.47, 2.34) | 0.90     |
| Focal cardiac necrosis              | Microthrombi                             | 1.23 (0.37, 4.14) | 0.74               | 1.03 (0.30, 3.56) | 0.96     |
| Focal inflammatory infiltrate       | Microthrombi                             | 0.43 (0.14, 1.35) | 0.15               | 0.39 (0.12, 1.25) | 0.11     |
| Focal myocarditis                   | Microthrombi                             | 1.27 (0.21, 7.85) | 0.80               | 1.30 (0.20, 8.52) | 0.78     |

All histopathologic features listed above were identified on immunohistologic microscopy with the exception of focal inflammatory infiltrate and myocarditis, which were identified by H&E staining. Details in Supplemental Methods. Multivariate model is adjusted with age and sex.
Supplemental Table 3. Association between detectable SARS-CoV-2 and acute histopathologic features at the ventricular level

| Histopathologic Feature                          | Univariate Model | Multivariate Model |
|-------------------------------------------------|------------------|--------------------|
|                                                 | OR (95% CI)      | p                  | OR (95% CI) | p |
| Microthrombi                                    | 1.52 (0.78, 2.99)| 0.22               | 1.62 (0.81, 3.22)| 0.17 |
| Microvascular endothelial cell damage           | 2.24 (1.00, 5.03)| 0.05               | 2.36 (1.04, 5.35)| 0.04 |
| Scattered individual necrotic cardiomyocytes    | 1.42 (0.66, 3.04)| 0.37               | 1.43 (0.67, 3.04)| 0.35 |
| Focal cardiac necrosis                          | 0.40 (0.12, 1.27)| 0.12               | 0.42 (0.13, 1.36)| 0.15 |
| Focal inflammatory infiltrate or myocarditis    | 0.30 (0.08, 1.03)| 0.06               | 0.28 (0.08, 1.04)| 0.06 |

All histopathologic features listed above were identified on immunohistologic microscopy with the exception of focal inflammatory infiltrate or myocarditis, which was identified by H&E staining. Details in Supplemental Methods. Multivariate model is adjusted with age and sex.
Supplemental Table 4. Association between cardiac microthrombi and ESR as a categorical variable.

| Quartile | ESR (mm/hr) | Unadjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-Value |
|----------|-------------|------------------------|---------|----------------------|---------|
| 1st      | 27.0-80.0   | Reference              |         |                      |         |
| 2nd      | 81.0-107.1  | 1.70 (0.65-4.50)       | 0.280   | 0.87 (0.24-3.23)     | 0.840   |
| 3rd      | 107.2-126.0 | 2.78 (1.08-7.17)       | 0.034   | 3.76 (1.17-12.04)    | 0.026   |
| 4th      | 130.0-169.1 | 1.95 (0.77-4.91)       | 0.160   | 6.65 (1.53-28.79)    | 0.011   |

Logistic regression model was adjusted for possible confounders by calculating a covariate balancing propensity score (CBPS) and using it as a single covariable. The covariates used to calculate CBPS were: age, sex, race/ethnicity, body mass index, duration of Covid-19 illness, outpatient ACEi/ARB use, outpatient antiplatelet therapy, and inpatient administration of corticosteroids, remdesivir, interleukin-6 (IL-6) receptor antagonists, and therapeutic anticoagulation.

ESR = Erythrocyte sedimentation rate, OR = odds ratio, CI = confidence interval
Supplemental Table. Clinical characteristics of COVID-19 (+) snRNAseq subset

| Study ID | Microthrombi (+) | Microthrombi (-) |
|----------|------------------|------------------|
| 05       | 05               | 05               |
| 39       | 39               | 39               |
| 61       | 61               | 61               |
| 19       | 19               | 19               |
| 45       | 45               | 45               |
| 51       | 51               | 51               |
| 66       | 66               | 66               |

**Baseline Characteristics**

| Age – yr | Sex          | Race/ethnicity | Body mass index – kg/m² | Obesity† | Hypertension | Diabetes | Insulin-dependent | Atherosclerotic disease‡ | Chronic lung disease§ | History of VTE¶ | Number of Comorbidities | Outpatient Medication Use | Clinical Course | Laboratory Studies, peak values | Covid-19 Therapies | In-hospital Anticoagulation | Prophylactic dosing | Therapeutic dosing |
|----------|--------------|----------------|-------------------------|----------|--------------|----------|------------------|------------------------|----------------------|-----------------|------------------------|------------------------|----------------|-------------------------------|-----------------|------------------------|-------------------|-------------------|
| 83       | Male         | Hispanic      | 24.0                    | -        | ✓            | -        | -                | -                      | -                    | -                | 1                      | -                      | 9              | 410                          | ✓               | ✓                      | ✓                 | -                  |
| 71       | Male         | Hispanic      | 34.7                    | ✓        | ✓            | -        | -                | -                      | -                    | -                | 2                      | ✓                      | 26             | 24                            | ✓               | ✓                      | ✓                 | -                  |
| 58       | Male         | Hispanic      | 28.5                    | ✓        | ✓            | -        | -                | -                      | -                    | -                | 1                      | -                      | 57             | 292                          | ✓               | ✓                      | ✓                 | -                  |
| 68       | Male         | Hispanic      | 32.0                    | -        | ✓            | ✓        | -                | -                      | -                    | -                | 1                      | -                      | 26             | ✓                            | ✓               | ✓                      | ✓                 | -                  |
| 65       | Male         | Hispanic      | 29.0                    | ✓        | ✓            | ✓        | -                | -                      | -                    | -                | 2                      | -                      | 24             | ✓                            | ✓               | ✓                      | ✓                 | -                  |
| 63       | Male         | Hispanic      | 34.5                    | ✓        | ✓            | ✓        | -                | -                      | -                    | -                | 2                      | -                      | 21             | ✓                            | ✓               | ✓                      | ✓                 | -                  |
| 69       | Female       | n/a           | 23.0                    | -        | ✓            | -        | -                | -                      | -                    | -                | 3                      | -                      | 40             | 61                            | ✓               | ✓                      | ✓                 | -                  |

n/a = not available (undocumented)

✓ Represents presence of trait/therapy/finding

· Represents absence of trait/therapy/finding

VTE = venous thromboembolic disease
ACE = angiotensin converting enzyme
ARB = angiotensin receptor blocker
hs = high-sensitivity
ESR = erythrocyte sedimentation rate

* Detected on IHC of right ventricle

† Body mass index (BMI) ≥30 kg/m²
‡ History of coronary artery disease, cerebrovascular disease, or peripheral arterial disease
§ Chronic obstructive pulmonary disease, asthma, or interstitial lung disease
¶ Deep venous thrombosis or pulmonary embolism
‖ Reflects the number of patients receiving only prophylactic and not therapeutic anticoagulation
Supplemental Table 6. Sample level quality control metrics for snRNAseq

| Study ID | Estimated Number of Nuclei | Mean Reads per Nucleus | Median Genes per Nucleus | Number of Reads | Total Genes Detected | Median UMI Counts per Nucleus | Microthrombi | Included in Analysis | Post QC Number of Nuclei |
|----------|----------------------------|------------------------|--------------------------|----------------|----------------------|-------------------------------|--------------|---------------------|--------------------------|
| 05       | 9,575                      | 10,223                 | 791                      | 97,892,749     | 28,791               | 1,122                         | Positive     | TRUE                | 7208                     |
| 39       | 3,497                      | 56,326                 | 758                      | 196,972,045    | 26,402               | 1,285                         | Positive     | TRUE                | 1846                     |
| 51       | 9,886                      | 21,626                 | 1,910                    | 213,804,137    | 35,115               | 3,979                         | Negative     | TRUE                | 5787                     |
| 19       | 14,427                     | 34,978                 | 2,072                    | 504,630,120    | 38,265               | 3,735                         | Negative     | TRUE                | 9947                     |
| 45       | 9,683                      | 31,419                 | 1,670                    | 304,235,656    | 35,936               | 3,092                         | Negative     | TRUE                | 6851                     |
| 66       | 9,150                      | 11,807                 | 1,607                    | 108,041,509    | 33,527               | 3,059                         | Negative     | TRUE                | 7840                     |
| 61       | 5,412                      | 15,253                 | 1,158                    | 82,552,819     | 31,457               | 1,871                         | Positive     | TRUE                | 4014                     |
| 69       | 3,905                      | 13,434                 | 266                      | 52,460,970     | 26,291               | 416                           | Positive     | FALSE               | 0                        |

Study ID: COVID-19(+) sample ID

Estimated Number of Nuclei: Number of droplets called as nuclei from CellRanger pipeline

Mean Reads per Nucleus: Average number of mapped reads per nucleus

Median Genes per Nucleus: Median number of genes detected in nuclei

Number of Reads: Total number of reads with multiplexing index matching a given sample

Total Genes Detected: Total unique gene IDs detected across all nuclei

Median UMI Counts per Nucleus: Median number of unique transcript molecules detected per nucleus

Microthrombi: Detection of cardiac microthrombi by immunohistochemistry (CD61 staining of corresponding ventricular tissue)

Included in Analysis: Use of this sample in downstream analysis pipeline

Post-QC Number of Nuclei: Number of nuclei retained following filtering for aberrant mitochondrial reads, intron/exon ratio, and doublet score